Search Results
STARTAR: ADT + apalutamide + RT + docetaxel for PSA-recurrent prostate cancer following RP
STARTAR: AR inhibition + ADT + apalutamide + RT + docetaxel for salvage in PSA recurrent PC after RP
Optimizing outcomes in PSA recurrent prostate cancer
STARTAR: one-year follow-up results
UpFrontPSMA trial: 177Lu-PSMA-617 and docetaxel in mHNPC
Dr. Renee Brady-Nicholls - Using PSA Dynamics to Optimize Docetaxel Scheduling in Prostate Cancer
APF in prostate cancer patients following radical prostatectomy: what happens next?
Dr. Kantoff on Evolving Role of Docetaxel in Prostate Cancer Treatment
Identification of High Risk Disease and Initial Management of Biochemical Recurrence
Addition of docetaxel to initial hormone therapy improves survival in prostate cancer
SAPROCAN: saracatinib and docetaxel for mCRPC
ADT plus docetaxel or bisphosphonates in hormone sensitive prostate cancer: Systemic review
